In practical applications, data stream classification faces significant challenges, such as high cost of labeling instances and potential concept drifting. We present a new online active learning ensemble framework for drifting data streams based on a hybrid labeling strategy that includes the following: 1) an ensemble classifier, which consists of a long-term stable classifier and multiple dynamic classifiers (a multilevel sliding window model is used to create and update the dynamic classifiers to effectively process both the gradual drift type and sudden drift type data stream) and 2) active learning, which takes a nonfixed labeling budget, supports on-demand request labeling, and adopts an uncertainty strategy and random strategy to label instances. The decision threshold of the uncertainty strategy is adjusted dynamically, i.e., when concept drift occurs, the threshold is gradually reduced to query the most uncertain instances in priority to reduce the request expense as much as possible. Experiments on synthetic and real data sets show that precise prediction accuracy can be obtained by the proposed method without increasing the total cost of labeling, and that the labeling cost can be dynamically allocated according to the concept drift.

No abstract

No abstract

Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is currently in a pandemic outbreak and has become a global health issue. In addition to primarily involving the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis.

No abstract